Skip to main content
Cyfuse Biomedical K.K. logo

Cyfuse Biomedical K.K. — Investor Relations & Filings

Ticker · 4892 ISIN · JP3311800001 T Manufacturing
Open in API
Filings indexed 36 across all filing types
Latest filing 2023-03-28 Audit Report / Informat…
Country JP Japan
Listing T 4892

About Cyfuse Biomedical K.K.

https://en.cyfusebio.com/

Cyfuse Biomedical K.K. is a research and development company specializing in regenerative medicine through its proprietary bio 3D printing platform technology. The company's core innovation is a scaffold-free method for fabricating three-dimensional tissues and organs by fusing cellular aggregates, known as spheroids. This approach allows for the creation of complex biological structures using cells exclusively. Cyfuse develops, manufactures, and commercializes its bio 3D printers, including the Regenova® and S-PIKE® systems. These technologies are aimed at advancing applications in drug discovery, preclinical research, and the development of cellular products for therapeutic tissue and organ regeneration.

Recent filings

Filing Released Lang Actions
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act of Japan. It serves as a formal certification by the CEO and CFO regarding the accuracy of the company's Annual Securities Report (Yuuka Shouken Houkokusho). Since it is a regulatory filing required by law to accompany the annual report but is not the annual report itself, and does not fit into other specific categories like M&A or dividends, it falls under the general regulatory filing category. FY 2022
2023-03-28 Japanese
内部統制報告書－第13期(2022/01/01－2022/12/31)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act in Japan. It details the company's framework, scope, and results regarding internal controls over financial reporting. This type of document is a standalone regulatory filing concerning audit and internal control standards, which falls under the 'Audit Report / Information' (AR) category in the provided schema.
2023-03-28 Japanese
有価証券報告書－第13期(2022/01/01－2022/12/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains detailed financial statements, business descriptions, and corporate information for the fiscal year ending December 31, 2022. It is filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. FY 2022
2023-03-28 Japanese
訂正有価証券届出書（新規公開時）
Share Issue/Capital Change Classification · 100% confidence The document is a 'Securities Registration Statement' (有価証券届出書) filed with the Kanto Local Finance Bureau by Cyfuse Biomedical K.K. It details the terms of a new share issuance (public offering) and secondary offering, including pricing, underwriting, and the intended use of proceeds. This type of regulatory filing for capital raising is classified as a 'Share Issue/Capital Change' (SHA) document within the provided schema.
2022-11-22 Japanese
訂正有価証券届出書（新規公開時）
Capital/Financing Update Classification · 95% confidence The document is a 'Yuka Shoken Todokesho' (Securities Registration Statement) filed with the Kanto Local Finance Bureau in Japan. It details a new share issuance (IPO/Public Offering) by Cyfuse Biomedical K.K., including offering amounts, underwriting details, and the use of proceeds. In the context of the provided filing categories, this document represents a formal regulatory filing for a capital raise, which falls under 'Regulatory Filings' (RNS) as it is a primary registration document for securities offering.
2022-11-14 Japanese
有価証券届出書（新規公開時）
Capital/Financing Update Classification · 98% confidence The document is a 'Yuka Shoken Todokesho' (Securities Registration Statement) filed with the Kanto Local Finance Bureau by Cyfuse Biomedical K.K. This is a formal regulatory filing required in Japan for companies planning to issue new shares or conduct an IPO. It contains detailed information on the offering, underwriting, and use of proceeds. Since it is a primary regulatory document for a securities offering and does not fit into the other specific categories like 10-K or ER, it is classified as a Regulatory Filing.
2022-10-27 Japanese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.